Tasly Pharmaceutical Group Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
2
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 4 to 11, 2026 · next Dec 4
- 1 fee due Jan 7, 2027The maintenance fee for Use of Salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease (US 9,072,745) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 3 fees due Feb 11 to 13, 2027 · next Feb 11
- 3 fees due Jun 8 to 17, 2027 · next Jun 8
- 1 fee due Oct 21, 2027The maintenance fee for Salvianolic acid compound T, preparation method therefor, and use thereof (US 10,626,077) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,883,228 | Composition for heart disease, its active ingredients, method to prepare same and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,034,398 | Traditional Chinese Drug Comprising Danshen Extracts and Sanqi Extracts and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,205,123 | Capsule of compound danshen dripping pills In force · From the USPTO record | In force | From the USPTO record | |
| US 9,072,745 | Use of Salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease In force · From the USPTO record | In force | From the USPTO record | |
| US 9,101,640 | Use of Danshensu, Notoginsenoside R1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder In force · From the USPTO record | In force | From the USPTO record | |
| US 10,071,989 | Substituted cinnamamide derivative, preparation method and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,211,310 | Use of a Chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction In force · From the USPTO record | In force | From the USPTO record | |
| US 9,795,648 | Pharmaceutical composition for treating headache, and preparation method thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,013,694 | Formulation of a micro drop pill and the preparation method thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,889,093 | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 31: 6 lapsed for an unpaid fee · 4 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 6 no status recorded